Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | A2B530 |
Synonyms | |
Therapy Description |
A2B530 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CEACAM5 (CEA), an LIR-1-based inhibitory receptor targeting HLA-A*02, and an shRNA targeting beta2 microglobulin, which potentially induce tumor cell killing and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |